Added therapeutic benefit regarding ESMO-MCBS and the French health technology assessment of drugs granted early access program

Fiona Y.‐V. Pham; Emmanuelle Jacquet; Adrien Monard; Liora Brunel; Jean Yves Blay; Nicolas Albin

doi:10.1016/j.annonc.2022.02.002

Back

Added therapeutic benefit regarding ESMO-MCBS and the French health technology assessment of drugs granted early access program

Letter 2022 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2022

Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019

Fiona Y.‐V. Pham, Emmanuelle Jacquet, Amina Taleb, Adrien Monard, Ghania Kerouani‐Lafaye, Florence Turcry, Liora Brunel, Françoise Grudé, Isabelle Yoldjian, Isabelle Sainte‐Marie, Lotfi Boudali, Jean Yves Blay, Nicolas Albin

Letter2022

Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox

Arnaud Bayle, Antoîne Italiano, Christophe Massard, Jean Yves Blay, Aurélien Marabelle

Article2008

The French National Nutrition and Health Program: 2001–2006–2010

Serge Hercberg, Stacie Chat-Yung, Michel Chauliac

Article2015

Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit

Ksenya Shchors, Aristea Massaras, Douglas Hanahan

Article2018

PRM268 - EVALUATION OF REAL-WORLD DATA COLLECTION AND EVIDENCE GENERATION FROM EARLY ACCESS PROGRAM

Dan Joseph Stein, M Soni